stockrowRadNet, Inc.
RDNT Healthcare Diagnostics & Research
RadNet, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 billion, up 11.5% from fiscal 2024.
- Revenue
- +25.0%
- EPS
- −47.4%
- Free cash flow
- −43.2%
- Total debt
- +21.2%
Quarter to June 2026, against a year earlier
Follow RDNT
Alert me
RadNet, Inc. (RDNT) Shares outstanding
RadNet, Inc.'s shares outstanding at the end of fiscal 2025 was $75.2M, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $78.7M. Over the past ten years it has ranged from $45.2M (fiscal 2015) to $75.2M (fiscal 2025) — the current reading is the highest in ten years. RadNet, Inc. ranks 23rd of 49 Diagnostics & Research companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $75.2M | 0.57% |
| FY2024 | $74.8M | 15.63% |
| FY2023 | $64.7M | 12.80% |
| FY2022 | $57.3M | 7.30% |
| FY2021 | $53.4M | 4.97% |
| FY2020 | $50.9M | 1.29% |
| FY2019 | $50.2M | 3.21% |
| FY2018 | $48.7M | 2.69% |
| FY2017 | $47.4M | 1.60% |
| FY2016 | $46.7M | 3.29% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Jun 2026 | $78.7M | 2.17% |
| Mar 2026 | $77.1M | 2.48% |
| Dec 2025 | $75.2M | (2.84%) |
| Sep 2025 | $77.4M | 2.46% |
| 42 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| SHC Sotera Health Company compare | $289.2M |
| QGEN QIAGEN N.V. compare | $207.8M |
| ADPT Adaptive Biotechnologies Corporation compare | $186.9M |
| VCYT Veracyte, Inc. compare | $82.8M |
| RDNT RadNet, Inc. | $78.7M |
| ICLR ICON PLC compare | $77.4M |
| CDNA CareDx, Inc. compare | $55.0M |
| BLLN BillionToOne, Inc. compare | $53.7M |
| GRAL GRAIL, Inc. compare | $46.8M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on RDNT
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement